The agenda includes:
Preparing positions on the evaluation of drugs:
- Tremfya (guselkumab) under the drug programme: “Treatment of moderate and severe plaque psoriasis (ICD-10: L40.0)”.
- Opdivo (nivolumab) under the drug programme: “Treatment of patients with advanced colorectal cancer (ICD-10: C18 – C20)”.
- Yervoy (ipilimumab) under the drug programmes: “Treatment of patients with advanced colorectal cancer (ICD-10: C18 – C20)”.
- Jardiance (empagliflozin) for the indication: type 2 diabetes mellitus, in patients taking at least one antidiabetic drug, with inadequately controlled diabetes and with very high cardiovascular risk.
Preparing positions on the legitimacy of granting consent for reimbursement of the medicinal product Ospolot (sulthiame) for the indications: epilepsy, drug-resistant epilepsy, drug-resistant epilepsy in the course of Rett syndrome.
Preparing a position on the legitimacy of granting consent for reimbursement of the foodstuff for particular nutritional uses Milupa Basic-P for the indications: methylmalonic aciduria, isovaleric aciduria, propionic aciduria, glutaric aciduria, citrulinaemia, CPS1 deficiency, type II hyperammonemia (OTC deficiency), maple syrup disease, Wolf-Hirschhorn syndrome, hypoglycaemia-hyperammonemia syndrome.